novo direct semaglutide Nordisk gets into the direct-to-patient game with Wegovy Novo Nordisk's semaglutide shows promise

, , -

JAMA Dermatol 2013

It does not work by manipulating your hormones or mimicking testosterone

The "minimal initial benefit" group (approximately 5-10% of users) reported limited improvements during treatment making discontinuation effects irrelevant, typically explained by inadequate product quality with degraded or low-concentration GHK-Cu, inappropriate application technique reducing absorption, unrealistic expectations exceeding what any topical can achieve, severe underlying pathology requiring medical intervention beyond cosmetic peptides, or individual non-responsiveness to copper peptide treatment for genetic or physiological reasons

Take the missed serving when you remember